Goldman Sachs analyst Jami Rubin downgraded Perrigo (PRGO) to Sell saying the stock, despite the recent selloff, "continues to trade at a premium that it does not deserve." Perrigo has morphed into a specialty pharmaceutical company as its consumer health business continues to struggle,

Rubin tells investors in a research note. She prefers Mylan (MYL) and Teva (TEVA) in the generic space. The analyst cut her price target for Perrigo shares to $124 from $160. The stock closed Friday down 95c to $129.45.